Fish Oil and BCQ™ as a Novel Treatment Approach to Primary Erythromelalgia: A Case Study

Erythromelalgia (EM) is a rare disorder, of which the pathophysiology is poorly understood. Though primary EM is thought to be an autosomal-dominant inherited disorder or of idiopathic origin, secondary EM is associated, most often, with myeloproliferative diseases. Pain management is the primary therapeutic target, however, individual patient responses vary widely, and no single treatment has been determined to be effective. As such, EM is often associated with reduced quality of life and higher morbidity and mortality. This case study examines an 81-year-old Caucasian female patient with a diagnosis of primary EM, for which previous pharmaceutical therapies had proven ineffective. Therapeutic intervention included a novel, daily supplement regimen of fish oil and BCQ™.